SEOUL, South Korea--(BUSINESS WIRE)--R-Japan, an affiliated company of Nature Cell (KOSDAQ: 007390), announced its business performance for 2016.
In 2016 R-Japan cultured and supplied a total of 1,055.9 billion stem cells for 5 affiliated hospitals including Nishihara Clinic. The company conducted regenerative medical treatment more than 3,500 times and achieved sales of KRW10.4 billion as well as the ordinary profit of KRW1.6 billion.
The patients who received the regenerative medical treatment with stem cells supplied by R-Japan did not have any side effects. This performance of the medical treatment for the past 1 year has been officially reported to Japan’s Ministry of Health, Labor and Welfare.
Moreover, the medical treatment’s effects regarding degenerative arthritis, critical limb ischemia, autoimmune disease and skin care have been gradually acknowledged. R-Japan reported the number of medical treatments for degenerative arthritis exceeded 650 and the satisfaction regarding its therapeutic effect was very high.
R-Japan is promoting the expansion of affiliated medical institutions in 27 regions including Hokkaido, Kansai, Kyushu, etc., expecting the earnest activation of the stem cell regenerative medical treatment in 2017. Moreover, the company is planning to expand the area of medical treatment to anti-aging and Alzheimer’s disease. The company expects to perform regenerative medical treatment more than 5,000 times and supply cells which will be worth more than 1.5 trillion won for this year.
From this March, production processes will be allocated to Nature Cell and the affiliated company R Bio, which received permission for manufacturing from Japan’s Ministry of Health, Labor and Welfare. Japan BioStar Stemcell Research Institute (Director: Jeong-chan Ra) will be established in the KOBE Biomedical Innovation Cluster.
About R-JAPAN
R-JAPAN Co., Ltd. is the advanced biotechnology company specialized in manufacturing mesenchymal stem cells regenerative therapy with stem cell technology of Biostar Stem cell Research Institute in Korea. R-Japan’s proprietary technology is to isolate, multiply, and store adult mesenchymal stem cells with ensuring genetic integrity. R-Japan currently cultures approximately 1,000 cases per month and has been evaluated by many medical institutions. As a result, R-Japan has been cultured 5,860 billion cells for 24,293 patients since stem cell processing facility was operated.
